Luciano Marraffini

This inventor holds 17 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: The Rockefeller University, Massachusetts Institute of Technology, The Broad Institute, Inc.. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Luciano Marraffini. Retrieved from https://idiyas.com/inventor/luciano-marraffini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 214(Granted Patents)

Location History:

Brooklyn, NY (US) (2021 - 2022)
New York, NY (US) (2017 - 2024)

Company Filing History:

17 out of 751

The Rockefeller University

patents

1 out of 8,586

Massachusetts Institute of Technology

patents

1 out of 486

The Broad Institute, Inc.

patents

where one patent can have more than one assignee

Years Active: 2017-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655405 - SEQUENCE SPECIFIC DEGRADATION OF SINGLE-STRANDED POLYNUCLEOTIDES WITH CARD1 NUCLEASE (2026-06-16),

2. 12295993 - Sequence specific antimicrobials (2025-05-13),

3. 12285467 - Sequence specific antimicrobials (2025-04-29),

4. 12285466 - Sequence specific antimicrobials (2025-04-29),

5. 12246061 - Sequence specific antimicrobials (2025-03-11),

6. 12168040 - Sequence specific antimicrobials (2024-12-17),

7. 11918631 - Sequence specific antimicrobials (2024-03-05),

8. 11497797 - Sequence specific antimicrobials (2022-11-15),

9. 11491210 - Sequence specific antimicrobials (2022-11-08),

10. 11491209 - Sequence specific antimicrobials (2022-11-08),

11. 11453874 - Enhancement of CRISPR gene editing or target destruction by co-expression of heterologous DNA repair protein (2022-09-27),

12. 11452765 - Sequence specific antimicrobials (2022-09-27),

13. 11377645 - Compositions and methods using Cas9 with enhanced spacer acquisition function (2022-07-05),

14. 11299732 - Compositions and methods for transcription-based CRISPR-Cas DNA editing (2022-04-12),

15. 11135273 - Sequence specific antimicrobials (2021-10-05),

Title: Luciano Marraffini: Pioneering Innovations in Molecular Biology and CRISPR-Cas Technology

Introduction:

Luciano Marraffini, a distinguished inventor in the scientific community, has made significant contributions to molecular biology and CRISPR-Cas technology. His innovative work continues to inspire advancements in gene editing and biotechnology.

Latest Patents:

Luciano Marraffini holds a total of 11 patents, with his latest patents focusing on "Sequence Specific Antimicrobials." These patents provide compositions and methods for selectively reducing antibiotic-resistant and virulent bacteria in mixed bacteria populations using clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Career Highlights:

Marraffini has worked at prestigious institutions like The Rockefeller University and The Broad Institute, Inc. during his illustrious career. His research and inventions have propelled the field of molecular biology forward, particularly in the realm of gene editing and antimicrobial strategies.

Collaborations:

Throughout his career, Luciano Marraffini has collaborated with esteemed colleagues such as David Bikard and Feng Zhang. These collaborations have led to groundbreaking discoveries and advancements in CRISPR-Cas technology, showcasing the power of teamwork in scientific innovation.

Conclusion:

In conclusion, Luciano Marraffini's pioneering inventions in molecular biology and CRISPR-Cas technology have solidified his reputation as a leading innovator in the scientific community. His dedication to advancing gene editing and biotechnology continues to shape the future of the field, inspiring researchers and inventors worldwide to push the boundaries of what is possible in science and technology.

Profile summary based on public USPTO records.